Reports Q3 revenue $213M, consensus $210.73M. “During the third quarter of 2024, we grew revenue by 11%, compared to the third quarter of ...

Myriad Genetics Inc (MYGN) reports robust revenue growth and strategic initiatives despite facing policy changes impacting ...

Investigation Details On October 31, 2024, it was revealed that UnitedHealth Group (“UnitedHealth”) would no longer cover GeneSight, Myriad’s genetic test to help determine which mental health ...

Global Breast Cancer Screening Tests Market was valued at approximately USD 2.93 billion in 2023 and is projected to grow with a healthy CAGR of 54.3% over the forecast period 2024-2032. Read the ...

Global Cardiovascular Genetic Testing Market is valued at approximately USD 9.07 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 11.2% over the forecast period ...

Myriad Genetics (MYGN) was informed on Friday, November 1, 2024, of an updated medical policy from UnitedHealthcare restricting access to ...

Myriad Genetics said it is in talks with UnitedHealthcare to ensure that enrollees continue to have access to its GeneSight mental health medication test after the insurer changed its coverage policy.

SALT LAKE CITY, Nov. 04, 2024 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, was ...